Objective: Although interest in nasal continuous positive airway pressure (nCPAP) to avoid intubation is increasing, there is limited data regarding patient selection and outcome. We sought to determine the baseline parameters associated with failure.
Introduction
The potential for the use of nasal continuous positive airway pressure (nCPAP) in neonates was identified decades ago, 1 and it is commonly used today. 2 The advent of sophisticated methods of mechanical ventilation and surfactant replacement therapy, however, resulted in their preferential acceptance as the standard approach for treatment of significantly premature infants with respiratory failure. 2 The complementary use of nCPAP to wean infants from mechanical ventilation is, however, strongly supported and practiced. 3, 4 Observational studies and anecdotal experience have led to the hypothesis that the use of nCPAP in significantly preterm infants who are spontaneously breathing, could reduce the incidence of chronic lung disease (CLD) without compromising mortality. 5, 6 In some centers, this elective use of nCPAP to avoid intubation is widely applied. 4, 7, 8 However, until recently, evidence evaluating such a strategy was limited. 9 The recent large COIN trial, although not showing a significant advantage of elective nCPAP, does support for the first time that it is as safe and effective as an alternative to aggressive intubation and surfactant treatment. 10 Nevertheless, although the COIN trial examined effectiveness in two weight strata, information on the optimum patient selection is very limited. In addition with only one large trail in the literature, projection of the likely outcomes of significantly preterm infants treated with elective nCPAP remains difficult.
We reported earlier on Poland's successful adoption of nCPAP using the variable-flow Infant Flow device (VIASYS Yorba Linda, CA, USA). 8 This process of adoption included an ongoing national registry of nCPAP use.
The primary aim of this study was to determine baseline factors that affect the outcome of very low birth weight (VLBW) infants with respiratory distress syndrome treated electively with nCPAP with the intention of avoiding intubation. We hypothesized that a multivariate analysis would reveal only a few parameters with significant effect. We felt that our findings would be useful not only clinically to refine outcome expectations and patient selection but also in designing future clinical research.
Methods
We prospectively identified two primary end points: Treatment Failure and Bad Outcome. Treatment Failure was defined as the need for intubation during nCPAP treatment or within 72 h of removal from nCPAP. Intubation guidelines were defined as a PaCO 2 >65, or pH<7.25, or FiO 2 >60 with SpO 2 >90% or more than three apneas in an hour. Bad Outcome was defined as either death before discharge, or grade 4 intraventricular hemorrhage (IVH), or cystic periventricular leucomalacia or severe CLD. The latter was defined as radiological evidence of lung disease and the need for supplemental oxygen or ventilation at 40 weeks post conceptual age. Other treatment-related outcomes were also tabulated: Clinical Risk Index for Babies score, CLD, grade 3 and 4 IVH, pneumothorax, use of surfactant, duration of nCPAP and duration of respiratory support. Ultrasound was used to diagnose IVH and periventricular leucomalacia. CLD was defined as radiological evidence of lung disease and the need for supplemental oxygen or ventilatory support at 36 weeks post conceptual age.
In all, 12 parameters were prospectively defined as independent variables that might potentially affect the dependent outcome variables. These included the following: estimated gestational age (EGA), Apgar score at 5 min, age at initiation of nCPAP, arterial blood gas before initiation of nCPAP (PaO 2 , PaCO 2 , pH, BE, FiO 2 and PaO 2 /FiO 2 ) and three derived parameters. Low weight for EGA was calculated based on a regression of these infants that identified the lower 10%. This approach was used, rather than standard fetal growth charts, because those charts classified most of the larger infants as small for gestational age. A pH <7.25 or a PaO 2 /FiO 2 <150 were identified as parameters associated with respiratory distress syndrome (RDS), consistent with criteria for rescue surfactant intervention.
Our registry database was started in 2003 and at the time included 6762 cases of nCPAP use. The database includes 61 parameters associated with demographics, clinical baseline status, treatment and outcomes. We queried the database for infants treated electively for RDS to avoid intubation. RDS was not strictly defined, but rather one of seven diagnostic indications for elective nCPAP. This identified 4672 cases, 1345 of which were 1500 g or smaller. In total, 169 cases were excluded because they had received surfactant with an elective intubation-extubation before initiation of nCPAP. Another 238 cases were excluded because they did not include complete primary outcomes data. The remaining 938 cases were included in our analysis.
Descriptive information was tabulated as percentage of proportions or median and Interquartile Range (IQR: twenty-fifth to seventy-fifth percentile). Univariate comparisons were tested for significance using chi-square for categorical data and t-tests for continuous data. All multivariate analyses were conducted using backward stepwise conditional logistic regression. They were conducted in two stages. The first stage, intended to identify the statistically significant independent variables, included all 938 cases. As some of the data for independent variables were missing, a second stage was conducted with just the significant independent variables included. As a result the final analyses represented the most statistically powerful regression model. Specifically, this resulted in inclusion of 625 out of 938 for Treatment Failure, and 907 out of 938 for Bad Outcome. In addition, in the situation in which continuous variables were found to be statistically significant (that is, EGA, FiO 2 and PaCO 2 ), categorical transformations were examined to determine whether they were more significant than the continuous variable. When they were they were used in the results.
Subsequent to the primary analysis, exploratory evaluations were undertaken. These analyses evaluated factors associated with both pneumothorax and CLD.
All statistical analyses were conducted using SPSS version11.04 (Chicago, IL, USA). Associations were considered statistically significant, and reported whether P<0.05.
Results
In total, 938 cases were included in this analysis. They were treated in 92 neonatal ICU's in Poland between 2003 and 2007 . Approximately a quarter of these units were Level III, and the balance Level II centers. The baseline characteristics of these infants are summarized in Table 1 . In all, 76% of the infants were and 999 g and 5% were between 450 and 750 g. As might be expected among spontaneously breathing VLBW infants, most of the 5-min Apgar scores were high. Typical gas exchange was within normal limits. Nevertheless, before initiation of nCPAP a significant number met our rescue surfactant criteria.
The median age at initiation of nCPAP treatment was 1 h (1 to 3 h IQR). The median duration of nCPAP treatment was 3 days (1 to 6 days IQR). The median duration of all respiratory support for survivors was 5 days (2 to 15 days IQR). In all, 31% of the infants required intubation and mechanical ventilation, and only 11% received surfactant. The Clinical Risk Index for Babies score, reflecting baseline status as well as response during nCPAP, was low (1 to 3 points IQR).
The adverse effects and outcomes are shown in Table 2 . The incidence of mortality (6.3%), CLD (6.4%), grade 3 and 4 IVH (5.5%), cystic periventricular leucomalacia (3.5%) and pneumothorax (3.4%) were all infrequent. There were two prospective primary outcomes. Treatment Failure, the need for intubation and mechanical ventilation, occurred in 31.2% of the population. Bad Outcome, defined as death, severe neurological complication or continued need for supplemental oxygen or ventilation at 40 weeks post conceptual age, occurred in 10.9% of the population.
Only 5 of the 12 suggested independent variables were identified by the logistic regression analysis as being significantly associated with either of the two key outcomes. Only EGA, pH<7.25 and PaO 2 /FiO 2 <150 were significantly associated with Treatment Failure (P<0.001, P ¼ 0.035 and P ¼ 0.018, respectively). Only EGA, low weight for EGA and FiO 2 were significantly associated with a Bad Outcome (P<0.001, P ¼ 0.008 and P<0.001, respectively). The relative magnitude of the effects on these outcomes can be seen in Figures 1 and 2 . The risk decreases with increasing EGA, bottom line. The total risk associated with the addition of the other significant factors, at any EGA, is represented by the other lines. The increase in risk associated with these additive factors is tabulated in Table 3 at two EGAs. As can be seen, their additive risk is clinically significant as well as modestly higher in the more mature infants.
Figures 3 shows the factors associated with CLD in survivors. Only EGA, low weight for EGA and baseline PaCO 2 were significantly associated with CLD (P<0.001, P<0.001 and P ¼ 0.007, respectively). The risk of CLD increased with decreasing EGA as reflected in the bottom line. However, the effect of the other two factors was more pronounced. Infants with a PaCO 2 above 40 tended to have more than twice the risk of CLD. Infants who were low weight for their EGA had four to five times the risk of CLD.
We also evaluated pneumothorax on a post hoc basis. The multivariate logistic regression analysis found that the incidence of pneumothorax was independently associated with EGA (P<0.001), 
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but not any of the other independent variables. The incidence of pneumothorax was also independently associated with increased risk of Treatment Failure (P ¼ 0.001) and Bad Outcome (P ¼ 0.01), but not CLD in survivors.
Discussion
We presented our broad experience in the elective use of nCPAP to avoid intubation in VLBW infants with RDS. We reported treatment success (that is, no need for intubation) in 69% of our patients. Survival was high and incidence of adverse effects in survivors relatively low. These outcomes are comparable with those reported by others. [10] [11] [12] [13] It is reassuring that our outcomes in routine use across nearly all the neonatal ICU's in Poland are comparable with that seen in more controlled situations.
We identified and quantified baseline factors associated with the risk of Treatment Failure, Bad Outcome and CLD in survivors. We believe that this is the only data describing either the interaction of EGA with other factors or the magnitude of these effects.
The increase in risk associated with increasing prematurity (that is, lower EGA) is broadly accepted in neonatology. Others have reported its relevance to the application of nCPAP. 10 We found that the baseline risk of nCPAP Treatment Failure and Bad Outcome increased somewhat linearly with decreasing EGA. In contrast, the baseline risk of CLD in survivors increased exponentially, essentially doubling for every 2 weeks decrease in EGA.
Our analysis identified two other factors, in addition to EGA, independently associated with the risk of Treatment Failure (that is, need for intubation). Either a pH <7.25 or a PaO 2 /FiO 2 ratio of <150 were associated with a small but clinically significant increase in risk. When both were present, the risk increased 76% above the baseline risk at 34 weeks EGA and increased 34% at 26 weeks EGA. These two parameters were included in this analysis as they reflected criteria often used in rescue surfactant trials. It is not surprising that nCPAP would be less effective in a group of infants with more severe respiratory failure; others have reported a similar effect. 14, 15 One might speculate that these infants with severe respiratory failure, who had nCPAP failure, would have better outcomes if they had been electively intubated and given surfactant. However, we think it is important to note that the infants meeting our rescue surfactant criteria did not have an increase in the risk of CLD or Bad Outcome. This point would best be confirmed in a randomized control trial.
For our analysis of outcomes, we created a composite variable, Bad Outcome. We felt that the traditional 'death or CLD', although appropriate for some situations, was inadequate owing to the imbalance in both frequency and long-term morbidity in VLBW infants. Therefore, we combined death with severe neurological findings and with CLD requiring respiratory support at 40 weeks post conceptual age. With this definition, two-thirds of the incidence of Bad Outcome was associated with death, and the balance with severe outcomes likely to be associated with significant long-term morbidity.
Our analysis identified two other factors, in addition to EGA, that independently affected the risk of Bad Outcome. These were low weight for EGA and a high FiO 2 . A FiO 2 before initiation of nCPAP of 0.50 was associated with about the same increased risk as being low weight for EGA. When both were present, the risk more than doubled across the range of EGA. An increase in the risk of Bad Outcome being associated with low weight for EGA is hardly a surprise. However, it is interesting that FiO 2 , but not PaO 2 /FiO 2 ratio, or PaO 2 was associated with increased risk. We speculate that this could be a result of inappropriately high FiO 2 levels or perhaps a reflection of subjective clinical assessment of the severity of respiratory failure. 
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Our analysis of CLD among survivors identified EGA, low weight for EGA and PaCO 2 as risk factors. Unlike that seen with Treatment Failure and Bad Outcome, EGA, although important, was not the primary risk factor. Rather the risk of CLD was four to five times higher in infants that were of low weight for their EGA, regardless of their EGA. The increased risk associated with a higher PaCO 2 (>40 mm Hg) before initiation of nCPAP was probably a reflection of early respiratory insufficiency and not hypoventilation, although it is not clear why pH or pH<7.25 were not associated with the risk of CLD.
The recently published COIN trial compared elective use of nCPAP to intubation, surfactant treatment and mechanical ventilation in a group of infants 25 to 28 weeks EGA. 10 They reported a comparable incidence of survival with CLD, but a higher level of pneumothorax associated with nCPAP. Our study population was on the average more mature, but included some infants even less mature. In the 303 infants treated with nCPAP in the COIN trial, the incidence of pneumothorax was 9.1%, 29% of the survivors had CLD and 59% needed to be intubated. Among those 259 infants in the same EGA range in our study, the incidence of pneumothorax was 3.3%, 9.7% of the survivors had CLD and 46% needed to be intubated.
In our population only those who were intubated and developed severe RDS eventually received surfactant. In our population with comparable EGA to the COIN trial, 46% were intubated but only 11% received surfactant. In the COIN trial, infants in both arms were much more likely to received surfactant (38% of the nCPAP group and 77% in the intubation and conventional ventilation group). Yet the rates of CLD in the two COIN study arms were comparable with each other, and markedly higher than seen in our comparable group. This suggests that, despite the comparability of EGA, the COIN infants were probably at higher risk of CLD. This is consistent with our findings that factors other than EGA have a marked effect on the risk of CLD. The fact that our TreatmentFailure rate was only slightly lower than the COIN population, but our incidence of CLD markedly lower, further support the idea that failure on nCPAP that results in delayed surfactant treatment need not be associated with increased CLD.
Risk of pneumothorax has been associated with nCPAP treatment. 10, 16 In the COIN trial, the risk was nearly triple (9%/3%) than seen in the intubated paitients. One could speculate that this might have offset some of the potential benefits of nCPAP. In our population, however, the rate of pneumothorax was comparable with the conventional ventilation arm in the COIN trial. We also found consistent with COIN, that pneumothorax was associated with an increased likelihood of Treatment Failure and not CLD. Although pneumothorax was not associated with CLD, we can only speculate that the increased incidence of pneumothorax might be a marker of less optimal respiratory support that is associated with CLD. We did observe that pneumothorax was associated with Bad Outcome, contrary to the COIN findings of a lack of association with mortality, grade 3 to 4 IVH, or cystic periventricular leucomalacia. This could be a result of our wider range of patients, but more likely is a result of the increased statistical power associated with our larger population.
Comparison of these observations to other studies should be carried out with care, specifically with some limitations of our study in mind. First of all, this is an observational study of clinical practice. There were no prospectively defined control group or rigid elective nCPAP criteria. However, the data collection was prospectively defined and carefully monitored for quality. Further, part of that monitoring included evaluation of use according to established guidelines. Although certainly Treatment Failure was more subjective than would be expected in a rigorously conducted trial. Second all these infants were treated with one type of nCPAP device, the variable-flow Infant Flow. Some physiological testing suggests this type of nCPAP device is more effective than others. 17 The Infant Flow device used in Poland also offers a bilevel nCPAP mode. The bilevel mode might result in different outcomes and effects, but the structure of the database made these impossible to examine.
Our findings also have some research implications. As suggested in an earlier paragraph, there is a need to compare the effectiveness of different nCPAP devices and modes. This applies not only among nCPAP devices, but also to other non-invasive ventilation and invasive strategies. Our analysis not only identifies significant risk factors, but also provides a picture of the relative magnitude of risk of outcomes across a range. Subtle device and strategy benefits are best evaluated in populations with high risk of failure, while applying some control of secondary risk factors. We feel our data could be useful for that purpose as well. As an example, a population of infants 26 to 28 weeks EGA with a baseline pH <7.25 would have a risk of Treatment Failure of about 50% and might be a good population within which to test bilevel nCPAP or non-invasive positive pressure ventilation.
Conclusion
We feel our experience confirms that nCPAP applied with Infant Flow can be safely used to avoid intubation in VLBW infants. Further, we anticipate our findings will not only help those using elective nCPAP to refine their practice, but also help those considering its elective use to establish reasonable guidelines and expectations. Finally, we hope our evaluation of relevant risk factors will be useful to those designing related clinical research.
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